Vilin Bio Med share price
NSE: VILINBIOPharmaceuticals & Biotechnology
Vilin Bio Med Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2023 · Issue price ₹30
Last close ₹50.85down ₹0.05 (0.10%)
Share price at the NSE close on 27 Oct 2026. Previous close ₹50.90.
27 Oct: open ₹48.45, high ₹50.85, low ₹48.40
52-week range of traded prices to 27 Oct 2026
₹18.95Low, 16 Dec 2025₹60.95High, 9 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹78 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.20
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.73
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 12,00066.7% delivered
Results
Standalone; ₹ crore.Vilin Bio Med half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +185.4%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +763.0%
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹33 Crup 237.32%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.78 Crup 1,071.46%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 5.5%
Revenue by half year
Peak revenue ₹33 Cr, half year to Mar 2026; lowest ₹4.10 Cr, half year to Sep 2022
Net profit by half year, a loss in red
- Net profit
- Loss
A loss in 1 of the 8 half years shown
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.1 | 8.2 | 7.6 | 8.2 | 4.5 | 10.3 | 9.7 | 32.6 |
| Net profit | 0.6 | 0.7 | 0.8 | −0.8 | 0.1 | 0.1 | 0.2 | 1.8 |
| Net margin | 13.5% | 8.4% | 10.1% | −10.0% | 2.8% | 1.0% | 1.6% | 5.5% |
Standalone. The 8 half years from Sep 2022, the first on record. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹42 Crup 185.37%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1.93 Crup 762.61%
- Net margin
- 4.6%
Revenue by year
Peak revenue ₹42 Cr, year to Mar 2026; lowest ₹12 Cr, year to Mar 2023
Net profit by year, a loss in red
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 12.3 | 15.8 | 14.8 | 42.3 |
| Net profit | 1.2 | 0.2 | 0.2 | 1.9 |
| Net margin | 10.1% | 1.0% | 1.5% | 4.6% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacture of Pharmaceutical Products, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Vilin Bio Med PE ratio and valuation
Price to earnings
At or below today's level on 29% of 196 trading days over the last year.
LowestHighest
Its median112.50Industry median28.32
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +79.7% | +689.1% | −77.2% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Vilin Bio Med insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 4 pledge filings of unclear kind · 11 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Vilin Bio Med competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Vilin Bio Med in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Concord DrugsCONCORD | 84 | 41.12 | – | +82.5% | +380.5% | 5.0% | 7.1% | 0.00% |
 Denis Chem LabDENISCHEM | 84 | 10.50 | 0.92 | +4.1% | −5.8% | 9.0% | 10.4% | 4.14% |
 Samrat PharmachemSAMRATPH | 83 | – | 1.22 | +4.7% | −145.8% | −3.2% | −2.7% | 0.00% |
 Cian HealthcareCHCL | 79 | – | 9.25 | −8.1% | – | −113.9% | – | 0.00% |
 Shelter PharmaSHELTER | 72 | 7.98 | 0.94 | +44.4% | +24.7% | 15.1% | – | 0.00% |
 Source Natural Foods & Herbal SupplSOURCENTRL | 71 | 18.85 | 2.75 | +63.1% | +20.6% | 15.6% | 16.7% | 0.00% |
 Vineet LaboratoriesVINEETLAB | 71 | 17.73 | 1.55 | +6.4% | – | 13.2% | 8.8% | 0.00% |
 Sunil HealthcareSUNLOC | 68 | 19.00 | 0.97 | −0.6% | +1,851.4% | 5.2% | 4.9% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Vilin Bio Med announcements
Oct 2026
Sep 2026
15 Sep · Board meeting
15 Sep · Updates
15 Sep · Updates
Vilin Bio Med share price by year
Each calendar year to 2025.Vilin Bio Med share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 20.95 | −4.8% | 31.00 | 17.00 |
| 2024 | 22.00 | −5.6% | 29.95 | 16.00 |
| 2023 | 23.30 | – | 28.50 | 20.05 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 30 Jun 2023.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 48.50 | 50.90 | 48.45 | 50.90 | 49.49 | 16,000 | 75.0% |
| 23 Oct 2026 | 49.40 | 50.95 | 49.40 | 50.95 | 49.92 | 12,000 | 100.0% |
| 22 Oct 2026 | 48.10 | 52.00 | 48.10 | 52.00 | 49.08 | 16,000 | 100.0% |
| 21 Oct 2026 | 50.60 | 52.95 | 50.60 | 50.60 | 51.71 | 28,000 | 85.7% |
| 16 Oct 2026 | 55.95 | 55.95 | 53.25 | 53.25 | 54.31 | 16,000 | 75.0% |
| 15 Oct 2026 | 54.50 | 54.65 | 54.50 | 54.65 | 54.63 | 28,000 | 100.0% |
| 14 Oct 2026 | 56.95 | 57.00 | 52.05 | 52.05 | 56.26 | 48,000 | 100.0% |
| 13 Oct 2026 | 54.50 | 54.50 | 54.50 | 54.50 | 54.50 | 4,000 | 100.0% |
| 12 Oct 2026 | 52.00 | 52.05 | 50.05 | 52.05 | 51.54 | 16,000 | – |
Prices in ₹ per share as traded, not adjusted.
Company details
- Chairperson and managing director
- MADHU SUDHAN YADAMAKANTI REDDY
- At the end of the quarter to Sep 2026
- NSE symbol
- VILINBIO
- ISIN
- INE0L4V01013
- Industry
- Pharmaceuticals & Biotechnology